In silico screening and identifying phytoconstituents of Withania somnifera as potent inhibitors of BRCA1 mutants: A therapeutic against breast cancer – PubMed Black Hawk Supplements

Abstract

Breast CAncer gene 1 (BRCA1) is an anti-oncogene that helps the cell repair damaged DNA and preserve genetic material. BRCA1 also acts as a cell growth suppressor and produces tumor suppressor gene (TSG) proteins, i.e., BRCA1 protein. Remarkably, BRCA1 mutations account for 90 % of hereditary breast cancer and a majority of hereditary ovarian cancer. Hence, we have considered three mutants of BRCA1 (R1699W, R1699Q, T1700A) in this study and adopted an in-silico approach to find the best possible phytochemical to inhibit these mutated proteins, enabling early breast cancer diagnosis. Perceiving the importance, many natural molecules from ancient medicinal plants are considered for molecular docking. Our findings suggest that though many molecules bind actively with the receptor’s active site, the top three phytoconstituents (27-Deoxy-14-hydroxywithaferin A, Withacoagulin, Somniferanolide) of Withania somnifera, commonly known as Ashwagandha, have high binding affinities and suitable pharmacokinetic properties, making these natural compounds potential drug candidates. Further, molecular dynamics (MD) simulation and the binding free energy calculation show stability and thermodynamically favourable. We can, therefore, draw the conclusion that these lead compounds act as potential inhibitors against BRCA1. However, wet lab experiments and clinical trials are recommended to ascertain its efficacy, hence the development of novel BRCA1 inhibitors.

Keywords: BRCA1; Molecular docking and molecular dynamics (MD) simulation; Withania somnifera.

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

• Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants – Withania somnifera (Ashwagandha), Tinospora cordifolia (Giloy) and Ocimum sanctum (Tulsi) – a molecular docking study.

  Shree P, Mishra P, Selvaraj C, Singh SK, Chaube R, Garg N, Tripathi YB. Shree P, et al. J Biomol Struct Dyn. 2022 Jan;40(1):190-203. doi: 10.1080/07391102.2020.1810778. Epub 2020 Aug 27. J Biomol Struct Dyn. 2022. PMID: 32851919 Free PMC article.

• Withania somnifera extracts induced attenuation of HIV-1: a mechanistic approach to restrict viral infection.

  Jadaun P, Harshithkumar R, Gaikwad SY, Seniya C, Borse S, Gawai AA, Chavan-Gautam P, Tillu G, Mukherjee A. Jadaun P, et al. Virol J. 2023 Aug 3;20(1):173. doi: 10.1186/s12985-023-02130-y. Virol J. 2023. PMID: 37537596 Free PMC article.

• Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.

  Tripathi MK, Singh P, Sharma S, Singh TP, Ethayathulla AS, Kaur P. Tripathi MK, et al. J Biomol Struct Dyn. 2021 Sep;39(15):5668-5681. doi: 10.1080/07391102.2020.1790425. Epub 2020 Jul 8. J Biomol Struct Dyn. 2021. PMID: 32643552 Free PMC article.

• Withania somnifera (L.) Dunal – Modern perspectives of an ancient Rasayana from Ayurveda.

  Mukherjee PK, Banerjee S, Biswas S, Das B, Kar A, Katiyar CK. Mukherjee PK, et al. J Ethnopharmacol. 2021 Jan 10;264:113157. doi: 10.1016/j.jep.2020.113157. Epub 2020 Aug 9. J Ethnopharmacol. 2021. PMID: 32783987 Review.

• Review on anticancerous therapeutic potential of Withania somnifera (L.) Dunal.

  Singh N, Yadav SS, Rao AS, Nandal A, Kumar S, Ganaie SA, Narasihman B. Singh N, et al. J Ethnopharmacol. 2021 Apr 24;270:113704. doi: 10.1016/j.jep.2020.113704. Epub 2020 Dec 25. J Ethnopharmacol. 2021. PMID: 33359918 Review.